GB-115
NootropicsApproved (Russia)Also known as: GB115, Rankvilon, N-(6-phenylhexanoyl)glycyl-L-tryptophanamide, N-(1-oxo-6-phenylhexyl)glycyl-L-tryptophanamide, Ph(CH2)5CO-Gly-L-Trp-NH2, CCK-4 retrodipeptide analog
GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept.
Overview
At A Glance
GB-115 was designed as a retro-dipeptide analog of the beta turn of cholecystokinin tetrapeptide and acts as a low-affinity blocker of central cholecystokinin receptors (PMID: 17886432, PMID: 30295186). In mice and rats, activation of cholecystokinin tetrapeptide type 2 receptors…
Overview
GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept. GB-115 is a retro-analog of the beta turn of cholecystokinin tetrapeptide, and conformational work identified a beta II turn as the structure responsible for its activity (PMID: 17886432, PMID: 24397028, PMID: 30295186). The stereochemistry matters. In the original series of analogs, the L-tryptophan compounds were anxiolytic and the D-tryptophan compounds anxiogenic, and GB-115 was selected as the L-tryptophan lead (PMID: 17886432). It acts as a low-affinity blocker of central cholecystokinin receptors. In mice and rats, activating cholecystokinin tetrapeptide type 2 receptors abolished its anti-anxiety effect and the compound prevented cholecystokinin-induced anxiety, while the alpha2 adrenoceptor antagonist yohimbine did not interact with it, which the authors read as a shared pharmacological target with cholecystokinin tetrapeptide (PMID: 23113301). The animal file is broad. Oral administration produced anxiolytic effects in outbred mice, BALB/c mice and outbred rats in open field and elevated plus maze tests (PMID: 24130989), antidepressant-like reduction of immobility in the forced swim test that was weaker than amitriptyline (PMID: 21476266), reduced average daily ethanol consumption and the alcohol deprivation effect in high-emotionality MR rats (PMID: 27590755), and reduced anxiety during benzodiazepine withdrawal in outbred and inbred rats (PMID: 22238979). A repeated theme is that the effect depends on the animal phenotype: strains with a passive response to emotional stress respond differently from active ones (PMID: 12910281). A study in four male rhesus monkeys under individual caging reported reduced stress-related behavior and a lower cortisol to DHEA-S ratio, comparable to phenazepam (PMID: 39847298). Safety and dependence data in animals are more complete than for most compounds sold this way. A preclinical package found no deaths after single oral administration at up to 6000 mg/kg in mice and 3500 mg/kg in rats, no irreversible organ changes over six months of oral administration in rats and rabbits, and no allergenic, immunotoxic or mutagenic activity and no effect on reproduction or offspring development (PMID: 20726348). After 30 days of daily administration to rats, stopping the compound produced no anxiety, aggression or convulsive signs, in contrast to diazepam withdrawal in the same experiment (PMID: 21899090). Oral bioavailability in rats was low at 4.65 percent for the crystalline substance, which is why later work compared micronized and reformulated versions (PMID: 18457023, PMID: 27017703). Human evidence is Russian and mostly unpublished in indexed journals. Thirty-one patients with generalized anxiety disorder were treated for 21 days, an effective daily dose was identified, and the authors described a fast anxiolytic effect with a stimulating component and favorable changes in attention parameters and reaction time (PMID: 31626171). That report does not describe randomization, blinding or a placebo arm in its published abstract. The Russian trial registry records that study as an open phase IIa pilot, followed by a double-blind, randomized, placebo-controlled multicenter trial sponsored by Valenta Pharm from April 2021 to December 2022, and the Russian product label cites two placebo-controlled trials of 168 and 220 patients, none of which is indexed in PubMed. On 29 December 2023 GB-115 was registered in Russia as the prescription tablet Rankvilon for anxiety states in neurasthenia and adjustment disorders. It has no FDA or EMA authorization, and the aerosol spray sold on the research chemical market is not the registered tablet and is a research-use-only compound in the US market.
Potential Research Fields
Chemical Information
IUPAC Name
Not yet available
CAS Number
678996-63-9
Molecular Formula
C25H30N4O3
Molecular Mass
434.5 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
None established in humans. Mechanism-based: the compound blocks central cholecystokinin receptors (PMID: 23113301), so concurrent drugs acting on that system are an untested interaction. It potentiated morphine analgesia in mice through supraspinal opioid mechanisms (PMID: 18239806), which makes combination with opioids a mechanism-based concern. It also has immunomodulating activity in mice, stimulating macrophage phagocytosis and the humoral immune response (PMID: 19145294), and suppressed an experimental inflammatory response in rodents (PMID: 22235394), neither of which has been characterized in people.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$59.99
—
1
1
nasal_spray
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
GB-115 aerosol spray, 10 mL | nasal_spray | 10 mL aerosol spray● In Stock | $59.99BEST | — | — |
Tracking since Sep 7, 2026 · 1 data point
Vendors Selling GB-115
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
View Full Dosage Guide →
Protocols, calculator & safety for GB-115
Research Score
0 PubMed studies
Quality Indicators
Data Completeness
63%Quick Facts
Half-Life
Not established in humans; the published rat pharmacokinetic work reported an absolute oral bioavailability of 4.65 percent for the crystalline substance and did not report a terminal half-life (PMID: 18457023)
Molecular Weight
434.5 g/mol
Administration
Oral, Intraperitoneal injection (animal studies), Aerosol spray (form sold on the research chemical market)
CAS Number
678996-63-9
Trial Phase
Approved (Russia)
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is GB-115 used for in research?
GB-115 is a synthetic dipeptide, N-(6-phenylhexanoyl)glycyl-L-tryptophan amide, designed at the Zakusov Research Institute of Pharmacology in Moscow. It belongs to a Russian program that builds short peptides as topological analogs of the active fragment of a regulatory peptide, the same approach that produced noopept and dilept. GB-115 is a retro-analog of the beta turn of cholecystokinin tetrapeptide, and conformational work identified a beta II turn as the structure responsible for its activity (PMID: 17886432, PMID: 24397028, PMID: 30295186).
The stereochemistry matters. In the original series of analogs, the L-tryptophan compounds were anxiolytic and the D-tryptophan compounds anxiogenic, and GB-115 was selected as the L-tryptophan lead (PMID: 17886432). It acts as a low-affinity blocker of central cholecystokinin receptors. In mice and rats, activating cholecystokinin tetrapeptide type 2 receptors abolished its anti-anxiety effect and the compound prevented cholecystokinin-induced anxiety, while the alpha2 adrenoceptor antagonist yohimbine did not interact with it, which the authors read as a shared pharmacological target with cholecystokinin tetrapeptide (PMID: 23113301).
The animal file is broad. Oral administration produced anxiolytic effects in outbred mice, BALB/c mice and outbred rats in open field and elevated plus maze tests (PMID: 24130989), antidepressant-like reduction of immobility in the forced swim test that was weaker than amitriptyline (PMID: 21476266), reduced average daily ethanol consumption and the alcohol deprivation effect in high-emotionality MR rats (PMID: 27590755), and reduced anxiety during benzodiazepine withdrawal in outbred and inbred rats (PMID: 22238979). A repeated theme is that the effect depends on the animal phenotype: strains with a passive response to emotional stress respond differently from active ones (PMID: 12910281). A study in four male rhesus monkeys under individual caging reported reduced stress-related behavior and a lower cortisol to DHEA-S ratio, comparable to phenazepam (PMID: 39847298).
Safety and dependence data in animals are more complete than for most compounds sold this way. A preclinical package found no deaths after single oral administration at up to 6000 mg/kg in mice and 3500 mg/kg in rats, no irreversible organ changes over six months of oral administration in rats and rabbits, and no allergenic, immunotoxic or mutagenic activity and no effect on reproduction or offspring development (PMID: 20726348). After 30 days of daily administration to rats, stopping the compound produced no anxiety, aggression or convulsive signs, in contrast to diazepam withdrawal in the same experiment (PMID: 21899090). Oral bioavailability in rats was low at 4.65 percent for the crystalline substance, which is why later work compared micronized and reformulated versions (PMID: 18457023, PMID: 27017703).
Human evidence is Russian and mostly unpublished in indexed journals. Thirty-one patients with generalized anxiety disorder were treated for 21 days, an effective daily dose was identified, and the authors described a fast anxiolytic effect with a stimulating component and favorable changes in attention parameters and reaction time (PMID: 31626171). That report does not describe randomization, blinding or a placebo arm in its published abstract. The Russian trial registry records that study as an open phase IIa pilot, followed by a double-blind, randomized, placebo-controlled multicenter trial sponsored by Valenta Pharm from April 2021 to December 2022, and the Russian product label cites two placebo-controlled trials of 168 and 220 patients, none of which is indexed in PubMed. On 29 December 2023 GB-115 was registered in Russia as the prescription tablet Rankvilon for anxiety states in neurasthenia and adjustment disorders. It has no FDA or EMA authorization, and the aerosol spray sold on the research chemical market is not the registered tablet and is a research-use-only compound in the US market.
What forms does GB-115 come in?
GB-115 is available in nasal_spray form.
How much does GB-115 cost?
Prices start at $59.99 across 1 verified vendor.
How do I compare GB-115 vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one.